Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide ER Single Dose Escalation in Healthy Adults
NCT06422624Phase 1Not yet recruiting
- Sponsor
- Bostal Pharma
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Bostal Pharma. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06422624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422624.